User:Mr. Ibrahem/Tepotinib

Tepotinib, sold under the brand name Tepmetko, is a medication used to treat non-small cell lung cancer (NSCLC). Specifically it is used in metastatic disease that has mesenchymal-epithelial transition (MET) exon 14 skipping. It is taken by mouth.

Common side effects include swelling, tiredness, nausea, diarrhea, muscle pain, low sodium, and shortness of breath. Other side effects may include pneumonitis and liver problems. Use in pregnancy may harm the baby. It is a kinase inhibitor that blocks MET.

Tepotinib was approved in Japan in 2020, the United States in 2021, and Europe in 2022. In the United Kingdom it costs the NHS about £7200 per month as of 2022. This amount in the United States costs about 22,800 USD.